The global spread of COVID-19 has brought significant impact to the pharmaceutical industry.

Analysis of global drug market

According to the data of IQVIA, the total sales volume of the global pharmaceutical market is shown in the figure below:

It is estimated that by 2026, China will rank second in the world.

Analysis of Chinese Drug Market

According to the data of IQVIA and China Hospital Drug Statistics Report, the market fell sharply in April 2022. With the effective control of the epidemic, the market performance gradually recovered.

Under the background of normalization of epidemic prevention and control, all channels gradually recovered to the scale before the epidemic, and online retail channels expanded rapidly.

The continuous implementation of various policies, in which the purchase with quantity is still the most important factor affecting the hospital drug market.

In recent years, the drug structure of hospitals in China has taken place significantly, among which anti-tumor and immune products have become the fastest growing category, while the share of anti infection and cardiovascular products has been significantly squeezed.

The top 20 varieties of Chinese hospital drugs have also changed.

The overall market size of Chinese medicine is expected to reach a compound growth rate of 3.7% in the next five years.

The continuous efforts of the medical reform policy have constantly reshaped the structure of China's drug market, but the overall trend is that the market size is still expanding. Under the background of huge population, aging, technological innovation and deepening medical reform, the potential of China's medical and health industry will be released rapidly.